Skip to main content
PRFX
NASDAQ Life Sciences

PRF Technologies Files for Resale of Shares Under Highly Dilutive $10M Equity Line

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$1.61
Mkt Cap
$1.359M
52W Low
$1.57
52W High
$17.95
Market data snapshot near publication time

summarizeSummary

PRF Technologies filed an F-1 to register the resale of 3,000,000 ordinary shares under a previously announced $10.0 million equity line, which could result in over 345% dilution for existing shareholders.


check_boxKey Events

  • Enables Resale of 3 Million Shares

    The F-1 registers up to 3,000,000 ordinary shares for resale by YA II PN, LTD., following a Standby Equity Purchase Agreement (SEPA) entered into on May 7, 2026.

  • Massive Potential Dilution

    The 3,000,000 shares registered for resale represent approximately 345% of the company's currently outstanding ordinary shares, indicating extreme dilution.

  • Up to $10 Million Capital Raise for Company

    The company may receive up to $10.0 million in gross proceeds from selling shares to YA under the SEPA, which will be used for R&D, working capital, and general corporate purposes.

  • Shares Sold at Discount to Market

    Shares will be purchased by YA at 97% of the lowest of three daily VWAPs, a discount that can exert downward pressure on the stock price.


auto_awesomeAnalysis

This F-1 registration statement enables the resale of up to 3,000,000 ordinary shares by YA II PN, LTD., following the Standby Equity Purchase Agreement (SEPA) announced on May 7, 2026. The company may sell up to $10.0 million worth of shares to YA at a discount to the daily volume weighted average price (VWAP), which can lead to significant downward pressure on the stock. The potential issuance of 3,000,000 shares represents approximately 345% of the current outstanding shares, indicating extreme dilution for existing shareholders. This substantial capital raise, at a significant discount and near 52-week lows, highlights the company's urgent need for funding to sustain operations, but at a very high cost to equity holders.

At the time of this filing, PRFX was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $1.57 to $17.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PRFX - Latest Insights

PRFX
May 13, 2026, 4:15 PM EDT
Filing Type: F-1
Importance Score:
9
PRFX
May 07, 2026, 4:45 PM EDT
Filing Type: 6-K
Importance Score:
8
PRFX
Apr 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
PRFX
Mar 27, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
PRFX
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
PRFX
Mar 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
PRFX
Feb 18, 2026, 9:38 AM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Feb 11, 2026, 8:54 AM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Feb 03, 2026, 4:16 PM EST
Filing Type: 6-K
Importance Score:
8
PRFX
Jan 20, 2026, 9:07 AM EST
Filing Type: 6-K
Importance Score:
7